IRIS
TROIANO, Maria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 30.347
AS - Asia 10.439
EU - Europa 10.000
SA - Sud America 2.942
Continente sconosciuto - Info sul continente non disponibili 1.600
AF - Africa 554
OC - Oceania 27
Totale 55.909
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 29.911
SG - Singapore 4.226
IT - Italia 2.852
CN - Cina 2.414
RU - Federazione Russa 2.315
BR - Brasile 2.293
HK - Hong Kong 1.299
SE - Svezia 1.200
DE - Germania 708
VN - Vietnam 697
FR - Francia 626
FI - Finlandia 613
GB - Regno Unito 561
UA - Ucraina 497
IN - India 337
BD - Bangladesh 312
AR - Argentina 244
CA - Canada 204
CI - Costa d'Avorio 203
IQ - Iraq 155
ID - Indonesia 139
JP - Giappone 123
TR - Turchia 120
MX - Messico 114
EC - Ecuador 110
NL - Olanda 109
ZA - Sudafrica 108
PK - Pakistan 98
CO - Colombia 93
BE - Belgio 84
SA - Arabia Saudita 81
ES - Italia 78
VE - Venezuela 69
PL - Polonia 63
AT - Austria 60
PH - Filippine 56
IR - Iran 52
UZ - Uzbekistan 51
IE - Irlanda 50
TN - Tunisia 46
MA - Marocco 44
CL - Cile 40
JO - Giordania 38
MY - Malesia 38
EG - Egitto 36
LT - Lituania 34
PY - Paraguay 32
JM - Giamaica 28
KE - Kenya 28
EU - Europa 24
PE - Perù 24
AU - Australia 21
AE - Emirati Arabi Uniti 20
IL - Israele 20
OM - Oman 20
CR - Costa Rica 19
CZ - Repubblica Ceca 19
ET - Etiopia 18
UY - Uruguay 17
BO - Bolivia 16
KZ - Kazakistan 16
DO - Repubblica Dominicana 14
NP - Nepal 14
PT - Portogallo 14
RO - Romania 14
AL - Albania 13
BG - Bulgaria 13
LB - Libano 13
AZ - Azerbaigian 12
DZ - Algeria 12
GR - Grecia 12
PA - Panama 12
PS - Palestinian Territory 12
SN - Senegal 12
KR - Corea 11
TT - Trinidad e Tobago 11
CH - Svizzera 10
AO - Angola 9
KG - Kirghizistan 8
TH - Thailandia 8
BB - Barbados 7
BH - Bahrain 7
HU - Ungheria 7
DK - Danimarca 6
EE - Estonia 6
GE - Georgia 6
NG - Nigeria 6
NZ - Nuova Zelanda 6
SY - Repubblica araba siriana 6
BY - Bielorussia 5
HN - Honduras 5
MD - Moldavia 5
QA - Qatar 5
SV - El Salvador 5
XK - ???statistics.table.value.countryCode.XK??? 5
HR - Croazia 4
KW - Kuwait 4
LK - Sri Lanka 4
MK - Macedonia 4
NI - Nicaragua 4
Totale 54.254
Salva come PNG Salva come JPEG
Città #
Fairfield 3.851
Ashburn 2.829
Woodbridge 2.754
Singapore 2.165
Houston 1.845
Chandler 1.816
Seattle 1.531
Cambridge 1.299
Hong Kong 1.299
San Jose 1.228
Wilmington 1.200
Jacksonville 1.164
Ann Arbor 1.141
Milan 1.100
Nyköping 895
Dallas 865
Beijing 637
Lawrence 448
Roxbury 432
Lauterbourg 411
Nanjing 381
New York 358
Los Angeles 330
Rome 329
Des Moines 301
Boardman 292
Helsinki 243
Bari 242
Princeton 239
Abidjan 203
São Paulo 199
Ho Chi Minh City 195
Columbus 192
Santa Clara 188
San Diego 173
Brooklyn 168
Council Bluffs 168
Inglewood 148
Buffalo 146
Hanoi 129
London 126
Munich 124
Tokyo 113
Chicago 109
Figino 93
Shenyang 93
Hebei 91
Rio de Janeiro 89
Nuremberg 88
Norwalk 87
Dong Ket 85
Nanchang 85
Frankfurt am Main 83
Moscow 81
Jakarta 80
Brussels 77
Dearborn 76
Jiaxing 72
Paris 69
Guangzhou 67
Tianjin 67
Turin 66
Orem 63
Baghdad 62
Toronto 60
Falkenstein 58
Montreal 58
North Bergen 57
San Francisco 55
Atlanta 54
Dhaka 54
Changsha 50
Johannesburg 50
Amsterdam 48
Warsaw 47
Belo Horizonte 46
Dublin 46
Quito 44
Shanghai 40
The Dalles 40
Washington 40
Denver 38
Pune 37
Tashkent 37
Jeddah 36
Stockholm 36
Salt Lake City 34
Brasília 33
Chennai 33
Phoenix 33
Marseille 32
Medellín 32
Naples 32
Amman 31
Curitiba 31
Da Nang 31
Lahore 30
Wuhan 30
Bologna 29
Mexico City 29
Totale 37.051
Salva come PNG Salva come JPEG
Nome #
A case report of double filtration plasmapheresis in an acute episode of multiple sclerosis 817
Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study 763
Sustained Efficacy, Safety and High Adherence Rate of Onabotulinum Toxin Type A in Chronic Migraine Patients: A Multicentric Prospective Real-Life Study 328
Defining the role of NG2-expressing cells in experimental models of multiple sclerosis. A biofunctional analysis of the neurovascular unit in wild type and NG2 null mice 268
The role of sexual dysfunction and attachment style in migraine related quality of life 256
Association between miRNAs expression and cognitive performances of Pediatric Multiple Sclerosis patients: A pilot study 248
Translational readthrough generates new astrocyte AQP4 isoforms that modulate supramolecular clustering, glial endfeet localization, and water transport 245
Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. 245
Long-term cardiac safety and tolerability of fingolimod in multiple sclerosis: A postmarketing study 231
A rare association of anti-alanine-transfer RNA synthetase (anti-PL12) syndrome and sporadic inclusion body myositis 231
A pattern of cognitive deficits stratified for genetic and environmental risk reliably classifies patients with schizophrenia from healthy control subjects 228
Signs and symptoms of COVID-19 in patients with multiple sclerosis 221
Association of Inflammation and Disability Accrual in Patients with Progressive-Onset Multiple Sclerosis 220
Correction to: Disability assessment using Google Maps (Neurological Sciences, (2022), 43, 2, (1007-1014), 10.1007/s10072-021-05389-7) 217
RELATIONSHIP OF COGNITIVE PERFORMANCES AND EMPLOYMENT STATUS IN PEOPLE WITH RELAPSING MULTIPLE SCLEROSIS 211
AQP4ex is crucial for the anchoring of AQP4 at the astrocyte end-feet and for neuromyelitis optica antibody binding 208
Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis 205
DP71 and SERCA2 alteration in human neurons of a Duchenne muscular dystrophy patient 200
Comparison of switch to fingolimod or interferon beta/glatiramer acetate in active multiple sclerosis 197
Assessing response to interferon-β in a multicenter dataset of patients with MS 196
Neuraxial analgesia is not associated with an increased risk of post-partum relapses in MS 194
Autophagy markers LC3 and p62 accumulate in immune‐mediated necrotizing myopathy 193
The clinical perspective: How to personalise treatment in MS and how may biomarkers including imaging contribute to this? 192
Prognostic indicators in pediatric clinically isolated syndrome 190
The Cost of Patients With Relapsing-Remitting Multiple Sclerosis Who Develop Neutralizing Antibodies While Treated With Interferon Beta 189
Aquaporin-4 autoantibodies in Neuromyelitis Optica: AQP4 isoform-dependent sensitivity and specificity. 187
Age-related changes of serum N-acetyl-aspartate in healthy controls. 187
A rare case of multiple sclerosis and McArdle disease 186
Gender differences in safety issues during Fingolimod therapy: Evidence from a real-life Relapsing Multiple Sclerosis cohort 185
Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies 183
Adhesion molecules and matrix metalloproteinases in Multiple Sclerosis: effects induced by Interferon-beta 182
Age and disability drive cognitive impairment in multiple sclerosis across disease subtypes 182
Lymphocyte subsets as biomarkers of therapeutic response in Fingolimod treated Relapsing Multiple Sclerosis patients 181
Comparative effectiveness of natalizumab and fingolimod treatment on cognitive functions in relapsing multiple sclerosis. ECTRIMS 2016 - Poster Session 2 177
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis 177
Investigating the role of microRNA and transcription factor co-regulatory networks in multiple sclerosis pathogenesis 173
A controlled trial of mitoxantrone in multiple sclerosis: serial MRI evaluation at one year. 171
A systematic review of the incidence and prevalence of comorbidity in multiple sclerosis: Overview 171
Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register 171
Host-Cell Type Dependent Features of Recombinant Human Aquaporin-4 Orthogonal Arrays of Particles-New Insights for Structural and Functional Studies 169
Age-related disability in multiple sclerosis 168
A systematic review of the incidence and prevalence of cancer in multiple sclerosis 167
Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients 166
The Prevention of Post-Partum Relapses with Progestin and Estradiol in Multiple Sclerosis (POPART'MUS) trial: rationale, objectives and state of advancement 165
Development of an aquaporin-4 orthogonal array of particle-based ELISA for neuromyelitis optica autoantibodies detection 163
A comparison of the brief international cognitive assessment for multiple sclerosis and the brief repeatable battery in multiple sclerosis patients 163
A systematic review of the incidence and prevalence of sleep disorders and seizure disorders in multiple sclerosis 163
The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis 163
Lymphocyte count and body mass index as biomarkers of early treatment response in a multiple sclerosis dimethyl fumarate-treated cohort 163
The cost of relapsing-remitting multiple sclerosis patients who develop neutralizing antibodies during interferon beta therapy 162
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of Multiple Sclerosis 161
Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. 160
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomized, double-blind trial. 159
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome. 157
A sequence variation in the MOG gene is involved in multiple sclerosis susceptibility in Italy 155
Tissue distribution of the readthrough isoform of AQP4 reveals a dual role of AQP4ex limited to CNS 155
Glatiramer Acetate induces pro-apoptotic mechanisms involving Bcl-2, Bax and Cyt-c in peripheral lymphocytes from Multiple Sclerosis patients 154
The brief international cognitive assessment for multiple sclerosis (BICAMS): Normative values with gender, age and education corrections in the Italian population 153
Comparative efficacy of switching to natalizumab in active multiple sclerosis 152
Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment 151
Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study 151
Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study. 150
Cerebrospinal fluid neurofilament light levels mark grey matter volume in clinically isolated syndrome suggestive of multiple sclerosis 150
SCLEROSI MULTIPLA E LAVORO: DATI PRELIMINARI 149
The use of immunosuppressant therapy for multiple sclerosis in Italy: A multicenter retroprospective study 148
Illness Perception and Well-Being Among Persons with Multiple Sclerosis and Their Caregivers 148
Cerebrospinal fluid neurofilament tracks fMRI correlates of attention at the first attack of multiple sclerosis. 147
The incidence and prevalence of comorbid gastrointestinal, musculoskeletal, ocular, pulmonary, and renal disorders in multiple sclerosis: A systematic review 147
Analisi longitudinale dei livelli sierici di ICAM-1 solubile e dei subsets di linfociti T in pazienti con Sclerosi Multipla a decorso remittente in trattamento con IFNb-1b 147
Comparative efficacy of first-line natalizumab vs IFN-β or glatiramer acetate in relapsing MS 146
Natalizumab discontinuation and disease restart in pregnancy: A case series 146
Load-dependent dysfunction of the putamen during attentional processing in patients with clinically isolated syndrome suggestive of multiple sclerosis. 146
BLOOD MMP-9 AND SICAM-1 AS MARKERS OF RIFN-B TREATMENT EFFICACY IN RELAPSING-REMITTING MS 145
Treatment decisions in multiple sclerosis-insights from real-world observational studies 145
Long-term disability trajectories in primary progressive MS patients: A latent class growth analysis 144
PBMC of Multiple Sclerosis Patients Show Deregulation of OPA1 Processing Associated with Increased ROS and PHB2 Protein Levels 143
Caregiver quality of life in multiple sclerosis: a multicentre Italian study 142
Verbal fluency deficits in clinically isolated syndrome suggestive of multiple sclerosis. 142
Aquaporin-4 Autoantibodies in Neuromyelitis Optica: AQP4 Isoform-Dependent Sensitivity and Specificity. 141
Multiple sclerosis registries in Europe – An updated mapping survey 141
Apolipoprotein E genotype does not influence the progression of multiple sclerosis 140
Defining reliable disability outcomes in multiple sclerosis 140
Comparison of fingolimod, dimethyl fumarate and teriflunomide for multiple sclerosis 140
Sclerosi Multipla e Lavoro: dati preliminari 140
Perivascular and endomysial macrophages expressing VEGF and CXCL12 promote angiogenesis in anti-HMGCR immune-mediated necrotizing myopathy 140
Epoch analysis of on-treatment disability progression events over time in the Tysabri Observational Program (TOP) 139
Predictors of long-term disability accrual in relapse-onset multiple sclerosis 139
Risk knowledge in relapsing multiple sclerosis (RIKNO 1.0) - Development of an outcome instrument for educational interventions 139
A systematic review of the incidence and prevalence of cardiac, cerebrovascular, and peripheral vascular disease in multiple sclerosis 139
Multiple Sclerosis Progression and Relapse Activity in Children 138
Implementation of the 'Sapere Migliora' information aid for newly diagnosed people with multiple sclerosis in routine clinical practice: a late-phase controlled trial. 137
Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study 137
Seroconversion and indolent course of COVID-19 in patients with multiple sclerosis treated with fingolimod and teriflunomide 137
An information aid for newly diagnosed multiple sclerosis patients improves disease knowledge and satisfaction with care 136
Comparative effectiveness of glatiramer acetate and interferon beta formulations in relapsing-remitting multiple sclerosis 136
Age-related vascular differences among patients suffering from multiple sclerosis 135
Psychosocial issue in children and adolescents with multiple sclerosis 135
A genome screen for multiple sclerosis in Italian families. 135
Silent lesions on MRI imaging – Shifting goal posts for treatment decisions in multiple sclerosis 135
Treating multiple sclerosis with natalizumab. 134
Totale 18.244
Salva come PNG Salva come JPEG
Categoria #
all - tutte 227.937
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 227.937
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.282 235 422 48 80 144 289 174 172 237 210 532 739
2022/20234.809 779 506 297 427 616 590 66 558 714 30 126 100
2023/20241.647 153 312 108 110 144 354 60 59 30 63 29 225
2024/20257.632 321 145 641 302 238 631 586 638 373 423 1.102 2.232
2025/202618.357 2.257 776 1.514 1.799 1.654 954 1.780 541 2.886 1.553 503 2.140
2026/2027593 593 0 0 0 0 0 0 0 0 0 0 0
Totale 55.909